Osteoarthritis
Conditions
Interventions
Sulfonda liver decanodium group:Sulfodagan-Gui Sodium Injection (Jiangsu Hengrui Company) 2.5mg was injected subcutaneously 12 hours after operation
Natreheparin calcium group:Subcutaneously injected Natreheparin calcium 57 IU/kg 6 hours after operation
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who were hospitalized for primary hip or knee arthroplasty for various reasons without contraindications (including total hip arthroplasty, artificial femoral head arthroplasty and total knee arthroplasty); 2. The subjects who signed the written informed consent; 3. Male patients or infertile female patients aged 18-80 years (e.g. postmenopausal women, women after hysterectomy or bilateral tubal ligation) or women who were not pregnant or had no pregnancy plan during the study period; 4. The subjects with normal coagulation function and no blood system diseases had no previous cerebral thrombosis, cerebral infarction and other vascular embolic diseases, and they did not use any anticoagulants within 3 months before the trial; 5. The subjects with preoperative BMI >= 20 had negative DVT in both lower limbs; 6. Before the experiment, the blood index of the patient indicated that the renal function was normal.
Exclusion criteria
Exclusion criteria: Patients meeting any of the following exclusion criteria should be excluded: 1. The influencing factors of low molecular weight heparin (LMWH) application (1) There was a history of severe active haemorrhage (within 3 months); (2) Patients with thrombocytopenia or history of thrombocytopenia (platelet count below 100 x 10^9 / L); (3) Hypersensitivity to heparin, natroparin calcium and pork products; (4) Acute bacterial endocarditis; (5) Congenital or acquired bleeding tendency and disease (within 3 months); (6) Uncontrolled ulcerative or angiodysplastic gastrointestinal diseases; (7) Hemorrhagic cerebrovascular disease or history of brain, spine or ophthalmic surgery within 3 months before randomization; (8) Patients with contraindication of anticoagulant therapy or patients with long-term oral anticoagulant due to previous diseases can not stop taking anticoagulant; (9) 5 times higher than the upper limit of normal value, kidney (muscle liver clearance rate < 30ml / min), abnormal heart function, uncontrolled hypertension and tumor patients; (10) Patients with lower extremity vascular disease; (11) Pregnancy test was positive; 2. Influencing factors related to other reasons (1) In the past 90 days, I have participated in the clinical trials of drugs and instruments for the prevention of DVT; (2) Patients who underwent bilateral joint replacement at the same time; (3) BMI < 20, DVT positive, prothrombin activity < 60%, history of thrombosis, creatinine clearance rate below 50ml / min; (4) Patients with previous history of thrombosis or varicose veins of lower limbs; (5) Patients who refused to participate or had poor compliance due to other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Color ultrasound of lower extremity vessels; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine blood cell tests;Coagulation function test; | — |
Countries
China
Contacts
Public ContactChen Lu
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed